Treatment of a subtype of asd

• 收藏
• 分享

专利权人:

Stalicla SA

发明人:

DURHAM, Lynn

申请号：

AU2018361568

公开号：

AU2018361568A1

申请日:

2018.11.06

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

The present invention is directed to a pharmaceutical composition comprising an Nrf2 inhbitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/